A Study Evaluating FMC-376
Phase 1/2
403
about 4.2 years
18+
15 sites in CA, FL, IN +7
What this study is about
Researchers are testing a treatment called FMC-376 for people with certain types of advanced solid tumors that have KRAS G12C mutations. The trial will involve different dose levels and last approximately 1540 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take FMC-376
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Adverse Events (AEs), Dose Limiting Toxicities
Secondary: Area Under Blood Concentration-Time Curve (AUC) of FMC-376, Clearance (CL) of FMC-376 from Blood Plasma, Disease Control Rate (DCR), Duration of Response (DOR), Elimination Half-life (t1/2) of FMC-376, Maximum Observed Plasma Concentration (Cmax) of FMC-376, Overall Response Rate (ORR), Overall Survival (OS)
Oncology